Published in Curr Cardiol Rev on August 01, 2009
Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis. PLoS One (2014) 0.83
Catastrophic cardiac amyloidosis. Cardiol Res Pract (2010) 0.78
Breaking down protein degradation mechanisms in cardiac muscle. Trends Mol Med (2013) 0.78
Molecular mechanisms of amyloidosis. N Engl J Med (2003) 7.75
Diagnosis and management of the cardiac amyloidoses. Circulation (2005) 3.96
Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol (2007) 3.12
The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM (1998) 2.81
Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood (1992) 2.81
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol (2003) 2.74
Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet (2001) 2.71
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica (2007) 2.44
Light-chain (AL) amyloidosis: diagnosis and treatment. Clin J Am Soc Nephrol (2006) 2.00
Amyloidosis and the heart: a comprehensive review. Arch Intern Med (2006) 1.68
Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet (2003) 1.64
Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta (2005) 1.58
Cardiac amyloidosis--an update. Indian Heart J (2004) 1.47
Amyloidosis and Waldenström's macroglobulinemia. Hematology Am Soc Hematol Educ Program (2004) 1.29
Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm (2007) 1.24
Vascular abnormalities in primary amyloidosis. Eur Heart J (2007) 1.13
Amyloidosis. Hematol Oncol Clin North Am (1999) 1.11
Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation (2005) 1.10
Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. J Am Coll Cardiol (1998) 1.02
Out-of-hospital cardiac arrest in patients with cardiac amyloidosis: presenting rhythms, management and outcomes in four patients. Resuscitation (2004) 0.93
Usefulness of pulsed tissue Doppler imaging for evaluating systolic and diastolic left ventricular function in patients with AL (primary) amyloidosis. Am J Cardiol (2002) 0.92
Serial echocardiographic observations in patients with primary systemic amyloidosis: an introduction to the concept of early (asymptomatic) amyloid infiltration of the heart. Mayo Clin Proc (1984) 0.88
Is elevated plasma B-natriuretic peptide in amyloidosis simply a function of the presence of heart failure? Am J Cardiol (2005) 0.85
Current treatment in cardiac amyloidosis. Curr Treat Options Cardiovasc Med (2006) 0.83
Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis. Eur Heart J (2002) 0.80
Therapy and management of systemic AL (primary) amyloidosis. Swiss Med Wkly (2006) 0.79
Congo red-positive cardiac kappa-AL amyloidosis in plasmacytoma -- case report and review of the literature. Acta Med Austriaca (2003) 0.78
An unusual case of cardiac amyloidosis. J Gen Intern Med (2007) 0.77
Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol (2013) 2.43
Amiodarone-induced alveolar hemorrhage. South Med J (2006) 1.59
Tricuspid valve malfunction and ventricular pacemaker lead: case report and review of the literature. Echocardiography (2006) 1.25
Tricuspid valve involvement in carcinoid disease. Echocardiography (2007) 0.96
Alveolar hemorrhage: an underdiagnosed complication of treatment with glycoprotein IIb/IIIa inhibitors. J Interv Cardiol (2006) 0.94
Tako-tsubo syndrome as a consequence of transient ischemic attack. Rev Cardiovasc Med (2006) 0.93
Real-time ultrasound guidance reduces total and major vascular complications in patients undergoing pulmonary vein antral isolation on therapeutic warfarin. J Interv Card Electrophysiol (2013) 0.84
Fever-induced ST-segment elevation with a Brugada syndrome type electrocardiogram. Ann Intern Med (2008) 0.84
Idiopathic polymorphic ventricular tachycardia with normal QT interval in a structurally normal heart. Pacing Clin Electrophysiol (2006) 0.84
Papillary fibroelastoma involving the left ventricular wall. Rev Cardiovasc Med (2003) 0.83
Response to Letter by May et al regarding article, "Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation" by Bassiouny et al. Circ Arrhythm Electrophysiol (2013) 0.78
Safety of repetitive nerve stimulation in patients with cardiac implantable electronic devices. Muscle Nerve (2013) 0.78
C-reactive protein: the harbinger of cardiovascular diseases. South Med J (2008) 0.77
Atrial flutter and myotonic dystrophy in a male adolescent treated with radiofrequency catheter ablation. Rev Cardiovasc Med (2007) 0.76
Worsening thoracic impedance as a ventricular tachyarrhythmia risk. Rev Cardiovasc Med (2014) 0.75
Lactic acidosis during nucleoside antiretroviral HIV therapy. South Med J (2004) 0.75
Electrical isolation of both left pulmonary veins by a single left atrial endocardial radiofrequency energy application: ablation of marshall bundle bypass. Pacing Clin Electrophysiol (2012) 0.75
Diffuse ST segment elevation: what's your diagnosis? Acute pericarditis. Tenn Med (2009) 0.75
Mitral valve prolapse: relationship of echocardiography characteristics to natural history. Echocardiography (2006) 0.75
Atrial fibrillation ablation. J Med Liban (2013) 0.75
A medical mystery--palpitations. J Electrocardiol (2014) 0.75
Severe mitral stenosis with atypical presentation: hemorrhagic pleural effusion--a case report and literature review. Tenn Med (2009) 0.75
Extraction of a tunneled jugular defibrillator lead via a superior approach. J Med Liban (2014) 0.75